COMPANY
IN HARMONY WITH LIFE

BioCompatibility Innovation (BCI) is a company founded in 2014 and regularly registered in the Italian National Register of Innovative Start-ups. BCI operates in the biomedical and biotechnology fields and has focused mainly on the development of new technologies for the improvement of the biocompatibility degree of biological implantable medical devices and food from animal origins.

Biocompatibility improvements of bioprosthetic tissues
FACTA NOT PROMISES

With particular reference to biological implantable biomedical devices, BCI has made its efforts in the field of bioprosthetic heart valves substitutes (BHVs). BCI designed and developed two patented processes for the treatment of soft animal tissues currently used to BHVs manufacture with the aim to increase their duration. The treatment called FACTA is effective for the inactivation of a particular antigenic epitope: the alpha-Gal molecule. Such xenogeneic antigen resulted present in mammalian animal tissues (except in humans and higher primates) and is responsible for the onset of dystrophic phenomena that affect the behaviour of commercially available BHVs, limiting their life to about 10/12 years from the implant thus obliging both surgeons to a repetitive replacement of the prosthesis and patients to an even burdensome surgery.



22 November 2020

Interview to Alessandro Gandaglia, CEO of BCI (7 in punto, TelePadova)

A clear and complete explanation of the FACTA Technology emerged within the interview realized by TelePadova to Alessandro Gandaglia (CEO of BCI). Check the full interview:
28 October 2020

Facta, the technology that doubles the life of heart valves

A Made in Italy technology that allows the doubling of the life of biological heart valves. The solution was developed by BCI, the innovative company led […]
28 October 2020

The history of BCI, the Italian startup that increase the duration of heart valves (Economy Magazine)

«The Italian startup BCI – BioCompatibility has developed a new technology which is able to double the duration of biological heart valves thanks to the implementation […]